X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1049) 1049
Newsletter (84) 84
Publication (81) 81
Book Review (19) 19
Book Chapter (18) 18
Newspaper Article (13) 13
Conference Proceeding (5) 5
Magazine Article (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (796) 796
hyperkalemia (653) 653
index medicus (404) 404
male (361) 361
female (326) 326
hyperkalemia - chemically induced (228) 228
middle aged (218) 218
hyperkalemia - prevention & control (207) 207
potassium - blood (203) 203
aged (189) 189
potassium (188) 188
hyperkalemia - etiology (180) 180
risk factors (168) 168
adult (162) 162
urology & nephrology (154) 154
mortality (137) 137
research (136) 136
hypertension (117) 117
medicine, general & internal (115) 115
care and treatment (110) 110
treatment outcome (101) 101
hyperkalemia - blood (95) 95
heart failure (93) 93
chronic kidney failure (87) 87
hemodialysis (87) 87
hyperkalemia - drug therapy (86) 86
animals (85) 85
hyperkalemia - therapy (84) 84
medical research (83) 83
cardiac & cardiovascular systems (81) 81
retrospective studies (81) 81
spironolactone (78) 78
kidney diseases (77) 77
medicine, experimental (77) 77
aldosterone (76) 76
risk (76) 76
renal dialysis (75) 75
medicine & public health (74) 74
chronic kidney disease (73) 73
patients (72) 72
chronic kidney-disease (71) 71
nephrology (71) 71
angiotensin-converting enzyme inhibitors - therapeutic use (69) 69
hyperkalemia - complications (69) 69
prevention (69) 69
management (67) 67
serum potassium (67) 67
health aspects (66) 66
mineralocorticoid receptor antagonists - therapeutic use (64) 64
heart-failure (63) 63
kidney failure, chronic - therapy (63) 63
pharmacology & pharmacy (63) 63
time factors (63) 63
analysis (62) 62
potassium - metabolism (62) 62
angiotensin-converting enzyme inhibitors - adverse effects (61) 61
hyperkalemia - diagnosis (59) 59
hypertension - drug therapy (59) 59
hypokalemia (59) 59
angiotensin (58) 58
diabetes (58) 58
pediatrics (57) 57
therapy (57) 57
complications and side effects (55) 55
heart failure - drug therapy (55) 55
adolescent (54) 54
drug therapy (54) 54
electrocardiography (54) 54
aged, 80 and over (53) 53
drug therapy, combination (53) 53
mineralocorticoid receptor antagonists - adverse effects (53) 53
renin-angiotensin system - drug effects (53) 53
blood-pressure (51) 51
child (50) 50
hyperkalemia - epidemiology (50) 50
insulin (50) 50
internal medicine (49) 49
blood pressure (47) 47
hyperkalemia - physiopathology (47) 47
abridged index medicus (46) 46
prognosis (45) 45
kidney failure, chronic - complications (43) 43
clinical trials (42) 42
electrolytes (42) 42
prospective studies (42) 42
sodium (42) 42
surgery (42) 42
drugs (41) 41
reports (41) 41
dialysis (40) 40
diuretics (40) 40
left-ventricular dysfunction (40) 40
spironolactone - therapeutic use (40) 40
double-blind (39) 39
kidney transplantation (39) 39
risk assessment (39) 39
cardiac patients (38) 38
kidneys (38) 38
infant, newborn (37) 37
hospitals (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1088) 1088
German (23) 23
French (17) 17
Japanese (12) 12
Polish (7) 7
Spanish (6) 6
Chinese (3) 3
Russian (3) 3
Dutch (2) 2
Italian (2) 2
Portuguese (1) 1
Serbian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS ONE, ISSN 1932-6203, 02/2016, Volume 11, Issue 2, p. e0145958
Background and Objectives Sudden cardiac death (SCD) is a severe burden of modern medicine. Aldosterone antagonist is publicized as effective in reducing... 
LONG-TERM | MILD | LEFT-VENTRICULAR DYSFUNCTION | SPIRONOLACTONE | MULTIDISCIPLINARY SCIENCES | MINERALOCORTICOID RECEPTOR ANTAGONISTS | ACUTE MYOCARDIAL-INFARCTION | DOUBLE-BLIND | PRESERVED EJECTION FRACTION | EPLERENONE | WORSENING RENAL-FUNCTION | Mineralocorticoid Receptor Antagonists - administration & dosage | Myocardial Infarction - mortality | Prospective Studies | Humans | Mineralocorticoid Receptor Antagonists - adverse effects | Death, Sudden, Cardiac - prevention & control | Treatment Outcome | Heart Failure - pathology | Hyperkalemia - pathology | Gynecomastia - etiology | Gynecomastia - pathology | Renal Insufficiency - etiology | Randomized Controlled Trials as Topic | Heart Failure - prevention & control | Renal Insufficiency - pathology | Myocardial Infarction - pathology | Death, Sudden, Cardiac - pathology | Survival Analysis | Myocardial Infarction - prevention & control | Odds Ratio | Heart Failure - mortality | Hyperkalemia - etiology | Prevention | Care and treatment | Corticosteroids | United States | Analysis | Mortality | Patient outcomes | Dosage and administration | Research | Aldosterone | Health aspects | Heart attack | Myocardial infarction | Heart | Drugs | Cardiac arrhythmia | Renal function | Clinical trials | Antagonists | Beta blockers | Subgroups | Hyperkalemia | Randomization | Risk assessment | Failure analysis | Libraries | Heart diseases | Gynecomastia | Patients | Studies | Side effects | Death | Infarction | Cardiovascular diseases | Kidney transplantation | Life Sciences
Journal Article
Reviews in cardiovascular medicine, ISSN 1530-6550, 2014, Volume 15, Issue 1, pp. 11 - 23
Journal Article
Journal of the American Geriatrics Society, ISSN 0002-8614, 08/2011, Volume 59, Issue 8, pp. 1513 - 1520
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2009, Volume 361, Issue 1, pp. 62 - 72
Journal Article
Endocrine Journal, ISSN 0918-8959, 2017, Volume 64, Issue 6, pp. 623 - 632
Patients with aldosterone-producing adenomas are treated using surgery, and patients with idiopathic hyperaldosteronism receive medical treatment using... 
Mineralocorticoid antagonist | Primary aldosteronism | Aldosterone-producing adenoma | Outcome | LONG-TERM | SURGERY | BILATERAL PRIMARY ALDOSTERONISM | RISK-FACTORS | MANAGEMENT | FOLLOW-UP | GLOMERULAR-FILTRATION-RATE | ENDOCRINOLOGY & METABOLISM | ADENOMAS | MINERALOCORTICOID ANTAGONISTS | ADRENALECTOMY | Follow-Up Studies | Renal Insufficiency, Chronic - etiology | Humans | Hyperaldosteronism - pathology | Middle Aged | Postoperative Complications - prevention & control | Male | Adrenocortical Adenoma - drug therapy | Hypertension - etiology | Incidence | Renal Insufficiency, Chronic - epidemiology | Hyperaldosteronism - physiopathology | Hyperkalemia - epidemiology | Hypertension - prevention & control | Female | Hyperkalemia - prevention & control | Retrospective Studies | Republic of Korea - epidemiology | Kidney - physiopathology | Severity of Illness Index | Hypokalemia - etiology | Adrenocortical Adenoma - surgery | Kidney - drug effects | Tertiary Care Centers | Adrenalectomy - adverse effects | Hospitals, University | Hypokalemia - prevention & control | Mineralocorticoid Receptor Antagonists - adverse effects | Postoperative Complications - epidemiology | Adrenocortical Adenoma - pathology | Hyperaldosteronism - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Renal Insufficiency, Chronic - prevention & control | Tumor Burden - drug effects | Hyperaldosteronism - surgery | Aged | Adrenocortical Adenoma - physiopathology | Renal Insufficiency, Chronic - chemically induced | Hypertension | Hyperkalemia | Renal function | Epidermal growth factor receptors | Medical treatment | Surgery | Hypokalemia | Aldosterone | Patients | Glomerular filtration rate | Geriatrics
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 23, pp. 2204 - 2213
Patients with type 2 diabetes at high risk for cardiovascular disease who were already taking a renin–angiotensin system blocker were randomly assigned to the... 
GLOMERULAR-FILTRATION-RATE | CHRONIC HEART-FAILURE | MEDICINE, GENERAL & INTERNAL | CONVERTING-ENZYME INHIBITORS | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | DOUBLE-BLIND | CARDIOVASCULAR MORTALITY | FOLLOW-UP | SYSTOLIC DYSFUNCTION | BLOOD-PRESSURE | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Patient Dropouts | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Kidney Diseases - epidemiology | Treatment Failure | Amides - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Hypokalemia | Female | Drug Therapy, Combination | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Fumarates - therapeutic use | Kidney Diseases - prevention & control | Amides - therapeutic use | Fumarates - adverse effects | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Renin - antagonists & inhibitors | Hyperkalemia - chemically induced | Aged | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Angiotensin Receptor Antagonists - therapeutic use | Myocardial infarction | Women | Creatinine | Cerebral infarction | End-stage renal disease | Stroke | Heart attacks | Kidneys | Diabetes mellitus | Cardiovascular disease | Coronary artery disease | Hypotension | Hyperkalemia | Renin | Angiotensin | Renal failure | Diabetes | Kidney diseases | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Kidney transplantation
Journal Article